The biggest news at the International AIDS Conference in Vienna on Tuesday was the release of the Centre for the AIDS Programme of Research in South Africa (CAPRISA) study that finds that a microbicide gel containing Gilead’s HIV drug tenofovir lowers the risk of HIV infection in women by 39%.
"This is very encouraging," UNAIDS Executive Director Michel Sidibe said. "It can be controlled by women, and put in 12 hours earlier, and that is empowering. They do not have to ask the man for permission to use it.